Objectives: Urodynamic investigations provide an objective, quantitative evaluation of urinary function in patients with benign prostatic obstruction(BPO). The effects of doxazosin, a selective α(1)-adrenoceptor antagonist, on urodynamic measurements were investigated in three double-blind, placebocontrolled clinical studies of the treatment of BPO. Methods: 302 normotensive and mildly hypertensive men with BPO were evaluated. Patients were randomized to receive doxazosin (1-4 mg o.d.) or placebo for 4-29 weeks. Results: Doxazosin significantly improved free urinary flow rates compared with placebo. Urodynamic studies confirmed that doxazosin was effective in improving urinary flow, and also showed a reduction in detrusor pressure,resulting in decreased voiding time and increased voided volume. Analysis of pressure-flow data demonstrated a significant reduction in a measure of urethral resistance in doxazosin-treated patients. Conclusion: These results indicate that doxazosin is an important treatment option for patients with troublesome lower urinary tract symptoms and BPO.

Keywords:
Benign prostatic obstruction, Lower urinary tract symptoms, Doxazosin, Urodynamics
This content is only available via PDF.
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.